Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. RMTI
RMTI logo

RMTI Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
0.967
Open
0.953
VWAP
0.95
Vol
150.21K
Mkt Cap
37.01M
Low
0.930
Amount
142.04K
EV/EBITDA(TTM)
--
Total Shares
39.41M
EV
22.29M
EV/OCF(TTM)
--
P/S(TTM)
0.49
Rockwell Medical, Inc. is a healthcare company. The Company develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. The Company operates in the hemodialysis market, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceuticals, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. Its hemodialysis concentrates products are used to sustain a patient's life by removing toxins and balancing electrolytes in a dialysis patient’s bloodstream. The Company is the supplier of liquid and dry, acid and bicarbonate concentrates for dialysis patients in the United States. The Company manufactures hemodialysis concentrates at its facilities in Michigan, South Carolina, and Texas, and the Company manufactures its dry acid concentrate mixers at its facility in Iowa.
Show More

Events Timeline

(ET)
2026-03-26
06:10:00
Rockwell Medical Q4 Revenue at $18.3M
select
2026-03-26
06:10:00
Sees Positive Operating Cash Flow in 2026
select
2026-01-20 (ET)
2026-01-20
06:10:00
Rockwell Medical Sees Q4 Gross Margin Rise to 22%
select
2026-01-12 (ET)
2026-01-12
06:20:00
Rockwell Medical Adds 30 New Customers in Western U.S.
select
2026-01-05 (ET)
2026-01-05
06:10:00
Rockwell Medical Extends Agreement with Major US Dialysis Provider to December 31, 2026
select
2025-11-12 (ET)
2025-11-12
06:08:39
Rockwell Medical reaffirms revenue forecast of $65M-$70M for FY25
select
2025-11-12
06:07:25
Rockwell Medical announces Q3 adjusted EPS of 0 cents compared to 9 cents in the previous year.
select

News

Newsfilter
9.5
10:40 AMNewsfilter
PinnedRockwell Medical Announces Q1 2026 Financial Results Release Schedule
  • Results Release Schedule: Rockwell Medical will release its financial and operational results for Q1 2026 on May 7, 2026, with a press release at 6:00 AM ET followed by a live webcast at 8:00 AM ET, ensuring timely access to critical information for investors.
  • Webcast Details: The webcast will be hosted by President and CEO Mark Strobeck, Ph.D., and CFO Jesse Neri, featuring a discussion of the Q1 results followed by a Q&A session, aimed at enhancing investor engagement and transparency.
  • Company Overview: Rockwell Medical focuses on developing, manufacturing, and commercializing hemodialysis products, committed to providing high-quality products and exceptional customer service to dialysis providers worldwide, highlighting its significance in the healthcare sector.
  • Industry Recognition: Rockwell Medical has been certified as a Great Place to Work® for four consecutive years and named one of Fortune's Best Workplaces in Manufacturing & Production™ in 2024 and 2025, reflecting the company's ongoing commitment to employee satisfaction and industry reputation.
seekingalpha
9.5
03-26seekingalpha
Rockwell Medical Q4 2025 Earnings Call Insights Highlight Operational Improvements and Growth Projections
  • Customer Base Diversification: Rockwell Medical now serves approximately 300 customers in the U.S., including all five leading dialysis providers, with long-term agreements expected to drive sales growth in 2026, thereby strengthening its market position.
  • Financial Performance Improvement: Q4 2025 net sales reached $18.3 million, a 15% increase from Q3, despite a 26% year-over-year decline, while gross margin improved from 14% in Q3 to 21%, indicating sustained profitability enhancements.
  • Product Portfolio Expansion: The company introduced a single-use bicarbonate cartridge approved by the FDA 510(k), with expected sales of approximately $1 million in 2026, further enriching its product line and enhancing market competitiveness.
  • Optimistic Future Outlook: Management projects adjusted EBITDA for 2026 to be between $1 million and $2 million, with positive cash flow expected to continue, and long-term goals include exceeding $100 million in annual sales by 2029, with gross margins approaching 30%.
seekingalpha
9.5
03-26seekingalpha
Rockwell Medical Reports Q4 Earnings Miss with Strategic Growth Plans for 2026
  • Financial Overview: Rockwell Medical reported a Q4 Non-GAAP EPS of $0.02 with revenues of $18.3 million, reflecting a 25.8% year-over-year decline, which missed market expectations and indicates short-term financial challenges for the company.
  • Cash Flow Position: Despite the revenue drop, the company generated $2.3 million in cash flow from operating activities in Q4, increasing its cash reserves to $25 million by year-end 2025, providing a buffer for future operations.
  • Annual Performance Comparison: In 2025, Rockwell Medical achieved net sales of $69.3 million, aligning closely with its annual guidance of $65 million to $70 million but falling short of the market consensus of $75.15 million, highlighting intensified market competition.
  • Future Growth Strategy: The company aims to drive sustainable, profitable growth in 2026 by adding new customers, renewing existing contracts, improving pricing and product mix, enhancing operational efficiencies, and selectively expanding its portfolio through disciplined partnerships, projecting Adjusted EBITDA between $1 million and $2 million.
moomoo
9.5
03-26moomoo
Rockwell Medical Reports Q4 Adjusted EPS of $0.02
  • Company Overview: Rockwell Medical is a healthcare company focused on developing and commercializing innovative products for the treatment of kidney disease and related conditions.

  • Financial Performance: The company reported adjusted earnings per share (EPS) of $0.02 for the fourth quarter, indicating a positive financial outlook.

  • Product Development: Rockwell Medical continues to advance its product pipeline, aiming to enhance treatment options for patients with chronic kidney disease.

  • Market Position: The company is positioning itself strategically within the medical industry to address unmet needs in kidney care, potentially expanding its market share.

moomoo
9.5
03-26moomoo
Rockwell Medical Reports Q4 Net Loss of $600,000
  • Company Overview: Rockwell Medical is a healthcare company focused on developing and commercializing innovative products for the treatment of end-stage renal disease and chronic kidney disease.

  • Financial Performance: The company reported a net income of $600,000 for the fourth quarter, indicating a positive financial trend and potential growth in their market segment.

seekingalpha
9.5
03-25seekingalpha
Rockwell Medical Set to Announce Q4 Earnings on March 26
  • Earnings Announcement Schedule: Rockwell Medical (RMTI) is set to announce its Q4 2023 earnings on March 26 before the market opens, with a consensus EPS estimate of $0.02, reflecting a 50% year-over-year decline.
  • Revenue Expectations Decline: Analysts forecast RMTI's Q4 revenue at $18.58 million, representing a 24.7% year-over-year decrease, indicating challenges and pressures the company faces in the current market environment.
  • Historical Performance Review: Over the past two years, RMTI has beaten EPS estimates 50% of the time and revenue estimates 63% of the time, demonstrating a degree of volatility in the company's financial performance.
  • Increased Market Attention: As the earnings report approaches, investor interest in Rockwell Medical is rising, particularly in light of preliminary sales data exceeding expectations, which may influence market perceptions of its future performance.
Wall Street analysts forecast RMTI stock price to rise
2 Analyst Rating
Wall Street analysts forecast RMTI stock price to rise
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
2.50
Averages
3.75
High
5.00
Current: 0.000
sliders
Low
2.50
Averages
3.75
High
5.00
H.C. Wainwright
H.C. Wainwright
Buy
downgrade
$2
AI Analysis
2026-03-30
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$2
AI Analysis
2026-03-30
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Rockwell Medical to $2 from $2.50 and keeps a Buy rating on the shares. The firm cites the company's "more modest" sales ramp for the target cut.
Maxim
Maxim
Buy
maintain
$5 -> $4
2026-03-27
Reason
Maxim
Maxim
Price Target
$5 -> $4
2026-03-27
maintain
Buy
Reason
Maxim lowered the firm's price target on Rockwell Medical (RMTI) to $4 from $5 and keeps a Buy rating on the shares. The firm cites the company's Q4 results with net sales below better-than-expected preliminary net sales, the analyst tells investors in a research note. Maxim further notes that while Rockwell continues to position itself within the at-home dialysis market, a growing segment that now accounts for roughly 10% of the total hemodialysis market, the firm is reducing its estimates given continued pressure from lower DaVita (DVA) contribution and limited visibility on certain revenue contributions.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for RMTI
Unlock Now

Valuation Metrics

The current forward P/E ratio for Rockwell Medical Inc (RMTI.O) is 33.00, compared to its 5-year average forward P/E of 3.50. For a more detailed relative valuation and DCF analysis to assess Rockwell Medical Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
3.50
Current PE
33.00
Overvalued PE
68.26
Undervalued PE
-61.25

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-796.31
Current EV/EBITDA
-54687.73
Overvalued EV/EBITDA
3413.00
Undervalued EV/EBITDA
-5005.62

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
0.55
Current PS
0.48
Overvalued PS
0.81
Undervalued PS
0.30

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

small cap stocks with a 87% win rate
Intellectia · 178 candidates
Market Cap: <= 2.00BRsi Category: overboughtWeekly Average Turnover: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
IMTE logo
IMTE
Integrated Media Technology Ltd
3.15M
GITS logo
GITS
Global Interactive Technologies Inc
6.25M
EVTV logo
EVTV
Envirotech Vehicles Inc
15.36M
SEGG logo
SEGG
Lottery.com Inc
25.77M
LSTA logo
LSTA
Lisata Therapeutics Inc
35.55M
AMOD logo
AMOD
Alpha Modus Holdings Inc
38.60M
best way to make 10 to 100
Intellectia · 45 candidates
Market Cap: 10.00M - 100.00MWeekly Average Turnover: >= 1,000,000Annual Revenue Yoy Growth: >= 0.0%
Ticker
Name
Market Cap$
top bottom
AMTX logo
AMTX
Aemetis Inc
98.64M
MIND logo
MIND
Mind Technology Inc
94.90M
HYFT logo
HYFT
MindWalk Holdings Corp
94.78M
SSTI logo
SSTI
SoundThinking Inc
93.71M
IROQ logo
IROQ
IF Bancorp Inc
91.20M
SYPR logo
SYPR
Sypris Solutions Inc
89.82M
price under $5
Intellectia · 22 candidates
Market Cap: <= 10.00BPrice: <= $5.00Relative Vol: >= 1.20Beta: HighRiskRsi 14: >= 60Moving Average Relationship: PriceAboveMA20
Ticker
Name
Market Cap$
top bottom
RIG logo
RIG
Transocean Ltd
5.10B
DNN logo
DNN
Denison Mines Corp
3.36B
TV logo
TV
Grupo Televisa SAB
1.74B
BAK logo
BAK
Braskem SA
1.31B
GROY logo
GROY
Gold Royalty Corp
1.10B
SES logo
SES
SES AI Corp
861.57M
also
Intellectia · 23 candidates
Market Cap: <= 2.00BPrice: <= $5.00Weekly Average Turnover: >= 1,000,000Month Price Change Pct: >= $20.00Annual Eps Yoy Growth: >= 50.0%
Ticker
Name
Market Cap$
top bottom
SLS logo
SLS
Sellas Life Sciences Group Inc
779.89M
UP logo
UP
Wheels Up Experience Inc
624.57M
STKL logo
STKL
Sunopta Inc
563.89M
ASPN logo
ASPN
Aspen Aerogels Inc
295.88M
FNKO logo
FNKO
Funko Inc
211.27M
SIDU logo
SIDU
Sidus Space Inc
183.59M
top performing penny stocks
Intellectia · 18 candidates
Market Cap: <= 1000.00MPrice: <= $5.00Weekly Average Turnover: >= 1,000,000Month Price Change Pct: >= $30.00Annual Revenue Yoy Growth: >= 10.0%
Ticker
Name
Market Cap$
top bottom
URG logo
URG
Ur-Energy Inc
726.09M
LWLG logo
LWLG
Lightwave Logic Inc
634.08M
SATL logo
SATL
Satellogic Inc
486.33M
TROO logo
TROO
TROOPS Inc
474.59M
AGL logo
AGL
agilon health inc
395.14M
IPSC logo
IPSC
Century Therapeutics Inc
366.05M
Top $1 stock
Intellectia · 3 candidates
Price: $0.70 - $1.30Beta: HighRiskWeekly Average Turnover: >= 1,000,000Month Price Change Pct: >= $30.00
Ticker
Name
Market Cap$
top bottom
UP logo
UP
Wheels Up Experience Inc
624.57M
BARK logo
BARK
Bark Inc
161.04M
RMTI logo
RMTI
Rockwell Medical Inc
48.47M

Whales Holding RMTI

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Rockwell Medical Inc (RMTI) stock price today?

The current price of RMTI is 0.9392 USD — it has decreased -1.16

What is Rockwell Medical Inc (RMTI)'s business?

Rockwell Medical, Inc. is a healthcare company. The Company develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. The Company operates in the hemodialysis market, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceuticals, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. Its hemodialysis concentrates products are used to sustain a patient's life by removing toxins and balancing electrolytes in a dialysis patient’s bloodstream. The Company is the supplier of liquid and dry, acid and bicarbonate concentrates for dialysis patients in the United States. The Company manufactures hemodialysis concentrates at its facilities in Michigan, South Carolina, and Texas, and the Company manufactures its dry acid concentrate mixers at its facility in Iowa.

What is the price predicton of RMTI Stock?

Wall Street analysts forecast RMTI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RMTI is3.75 USD with a low forecast of 2.50 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Rockwell Medical Inc (RMTI)'s revenue for the last quarter?

Rockwell Medical Inc revenue for the last quarter amounts to 18.35M USD, decreased -25.62

What is Rockwell Medical Inc (RMTI)'s earnings per share (EPS) for the last quarter?

Rockwell Medical Inc. EPS for the last quarter amounts to -0.01 USD, decreased -66.67

How many employees does Rockwell Medical Inc (RMTI). have?

Rockwell Medical Inc (RMTI) has 157 emplpoyees as of April 09 2026.

What is Rockwell Medical Inc (RMTI) market cap?

Today RMTI has the market capitalization of 37.01M USD.